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Introduction
Atrial ﬁbrillation (AF) currently affects over 33 million people
worldwide with increasing prevalence in the United Kingdom
and globally.1,2 Current national and international guidance
recommends that female AF patients with a CHA2DS2-VASc
score of 2 and male patients with a score of 1 should be







Abstract Objective Oral anticoagulant (OAC) prescription for stroke prevention in atrial
ﬁbrillation (AF) patients frequently does not follow current guidelines, with underuse
in patients at high risk of stroke and substantial overuse in those at low risk. This review
aims to systematically evaluate the effectiveness of interventions to improve appro-
priate OAC prescription in eligible AF patients for stroke prevention.
Methods Systematic review of controlled and uncontrolled studies published up to
July 2017 with interventions designed to improve appropriate OAC prescription for
stroke prevention in eligible AF patients (according to risk assessment tool or guide-
lines). Categorization of intervention types was pre-speciﬁed. The main outcome was
change in proportion of eligible AF patients prescribed OACs for stroke prevention.
Results Twenty studies conducted in 392 settings were included (cluster randomized
controlled trials, controlled trials and uncontrolled before-after designs; n ¼ 29,868
patients at baseline). Fifteen studies reported signiﬁcant improvements in appropriate
prescription of OACs in AF patients. All interventions with a persuasive element (8/8); all
studies targeting health care professional (HCP) education or guideline/protocol imple-
mentation (7/7); and all medical care programs (4/4) achieved signiﬁcant increases in
appropriate OAC prescription. Computerized decision support interventions (3/5) and
reviews of prescribing (2/4) were less likely to report signiﬁcant improvements in
appropriate OAC prescription.
Conclusion Interventions designed to improve appropriate prescription of OACs in
eligible AF patients for stroke prevention can be effective. Successful approaches include
education of HCPs; implementation of local guidelines; interdisciplinary medical care
programs educating both HCPs and patients and persuasive interventions utilizing peer-
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antagonists (VKAs) and non-VKA oral anticoagulants (NOACs)
to reduce risk of stroke3–5 (taking bleeding into account using
theHAS-BLED score6). Over the last decade, rates of OAC use for
stroke prevention in newly diagnosed AF patients have steadily
increased to 71% worldwide7; reaching around 80% in Europe
and theUnitedStates.7,8However, there is still substantial room
for improvement in appropriate, guideline-adherent, OAC pre-
scribing. Worldwide, around half of all newly diagnosed AF
patients with a CHA2DS2-VASc score of 0 (low risk) are pre-
scribed OACs contrary to guideline advice, putting them at
unnecessary risk of haemorrhage.7 Conversely, of all high-risk
U.K. patients with a CHA2DS2-VASc score of 2 only 68% are
receiving OACs, falling to 40% in India and 31% in China,7
exposing many to a risk of stroke. Under-prescription of OACs
in patients aged 65 years and above has also been reported
across Europe.9
Research has explored possible reasons for under-pre-
scription of OACs in AF patients, with general practitioners
(GPs) reporting feeling responsible for haemorrhages in anti-
coagulated patients.10 Patients’ co-morbidities and concerns
about their ability to achieve adequate time in therapeutic
range may create barriers to the prescription of VKAs.10
Health care professionals (HCPs) may be especially reluctant
to prescribeOACs to older adults due to a perceived increased
likelihood of falls and subsequent haemorrhage; however,
research suggests that stroke risk is much greater in older
adults with AF, making anticoagulation more vital.10
Interventions have attempted to improve HCPs’ adher-
ence to guidelines in prescribing OACs to AF patients,11 but
there is no clear evidence regarding which intervention
design and theoretical framework is most effective. This
article presents the ﬁrst review to systematically evaluate
the effectiveness of interventions with any comparator
designed to improve appropriate prescription of OACs in
eligible AF patients for stroke prevention.
Methods
Protocol and Registration
The systematic methodology of this review was based on the
Cochrane Collaboration handbook12 and the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses state-
ment.13 The review protocol was registered on PROSPERO
prior to conducting literature searches (CRD42016039654).
Eligibility Criteria
Quantitative studies reporting interventions designed to
increase the rate of prescription of OACs for stroke preven-
tion in AF patients eligible for OAC treatment, or to improve
adherence to guidelines, were considered for inclusion.
Patients eligible for OAC treatment were deﬁned as
CHA2DS2-VASc score of 2 if female, 1 if male, or equiva-
lent risk stratiﬁcation tool, or stated as eligible according to
guidelines. Eligible study designs included controlled stu-
dies (randomized or non-randomized, prospective or retro-
spective, concomitant or historical control) and
uncontrolled before-after studies with any comparator.
Studies focusing on any HCP prescriber in any health care
setting were eligible. Interventions designed to improve
both HCPs’ prescription of and patients’ uptake/adherence
to OACs were eligible provided the rate of OAC prescription
was reported. Interventions were categorized as ‘Persua-
sive’ and/or ‘Educational and informational’, and/or ‘Action
and monitoring’, according to Johnson and May’s interven-
tion types for behavioural change in HCPs.14 Studies with an
outcome describing change in the proportion of AF patients
eligible for OAC treatment who were prescribed OACs by
HCPs for stroke prevention were included (or change in the
proportion of such patients taking OACs, if the intervention
was aimed only at improving HCPs’ prescription and not
patient uptake).
Studies including patients with a CHA2DS2-VASc score
of < 2 if female or < 1 if male (or ineligible for OACs on an
equivalent risk stratiﬁcation tool or according to guidelines)
were excluded from this review. Interventions focusing only
on the patient, or studieswhose outcomewas the proportion
of patients eligible for OACs who were taking OACs, where
the intervention was aimed at both the patient and the
health professional were excluded. Qualitative studies and
case series were also excluded from this review.
Literature Searches
Searches were performed with no language/publication
date restrictions from inception to June 2016 in the biblio-
graphic databases, including MEDLINE and MEDLINE in
Process, EMBASE, PsycINFO, CINAHL and The Cochrane
Library (CDSR, DARE and CENTRAL); Science Citation Index
(Web of Science) for citation searching; World Health
Organization International Clinical Trials Registry Platform
and Clinical Trials.gov for trials in progress; Conference
Proceedings Citation Index; Open Gray; and the Health
Management Information Consortium for grey literature
and bibliographies of relevant articles. A combination of
text words and index terms related to the condition (AF),
the therapy (OAC) and the intervention (interventions to
increase appropriate OAC prescription) were utilized
(►Supplementary Fig. S1, available in the online version).
A search update was performed up to July 2017 using the
limits ‘therapy’ and ‘best balance’ to concentrate the search
on OAC therapy, locating relevant papers while avoiding
irrelevant material.
Study Selection Process
Search results were exported to EndNote V.X7.4 (Thomson
Reuters, New York, New York, United States) and duplicates
removed. Titles and abstractswere read for relevance and full-
text versions of potentially eligible publications obtained.
Non-English languagearticleswere translated.A standardized,
pre-determined, studycriteria formwas applied to all full-text
documents,with ineligible publications and reasons for inelig-
ibility recorded (►Supplementary Table S1, available in the
online version).
Data Extraction and Quality Assessment
Data were extracted using a standardized, piloted data extrac-
tion form. Discrepancies were compared with original data.
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Information on following characteristics was extracted: study
design, health care setting, AF type and risk stratiﬁcation,
intervention/comparator arms, intervention-deliverer, target
population and ﬁndings. The theoretical focus of the interven-
tion was determined based on the categories suggested by
Johnson and May: persuasive interventions (marketing, mass
media, local consensus processes, local opinion leaders); edu-
cational and informational interventions (educational materi-
als and meetings); and action and monitoring interventions
(audit and feedback, reminders).14
Risk of bias assessment was tailored to different study
designs. The Cochrane Collaboration’s risk of bias tool was
used to quality assess randomized controlled studies15
(►Supplementary Fig. S2, available in the online version);
an adjusted version was used for non-randomized controlled
studies (►Supplementary Fig. S3, available in the online
version). TheNational Institutes ofHealth (NIH)RegionalHeart,
Lung and Blood Institute Quality Assessment Tool for observa-
tional, cohort and cross-sectional studies was used to assess
risk of bias in cross-sectional studies16 (►Supplementary
Fig. S4, available in the online version); and an adapted version
of theNIHQualityAssessmentTool forbefore-after studieswith
no control groupwas used to assess risk of bias in uncontrolled
before-after studies16 (►Supplementary Fig. S5, available in
the online version).
All study selection, data extraction and quality assess-
ment processes were conducted independently and in dupli-
cate; discrepancies were resolved by an additional reviewer.
Data Synthesis
As study designs were heterogeneous, a narrative synthesis
was conducted. Tables of characteristics were created for
eligible controlled and uncontrolled studies (►Tables 1
and 2; further details in ►Supplementary Table S2, available
in the online version). To facilitate comparison, data were
summarized in a standardized way. Results were considered
by different characteristics and risk of bias to elicit systema-
tic differences (►Table 3). It was not possible to formally
assess possible publication bias.
Results
This review identiﬁed 12,807 records, of which 72 were
assessed for full eligibility; of these, 52 did not meet elig-
ibility criteria (►Supplementary Table S1, available in the
online version). Twenty studies were included in this review
and informed the analysis (►Fig. 1). Protocol papers of four
on-going studies were located.17–20
Study Characteristics
The 20 included studies were conducted at 392 individual
health care settings (including GP surgeries and secondary/
tertiary care hospitals) (►Tables 1 and 2). At baseline,
29,868 patients were included; 11,105 in controlled and
18,763 in uncontrolled studies. Study designs included 3
cluster randomized controlled trials (RCTs),21–23 5 con-
trolled studies,24–28 1 cross-sectional study29 and 11
uncontrolled before-after studies.30–40
Intervention Design
Of the 20 studies, one provided an educational intervention
with an expert panel,40 threewere based on implementation
of local or national clinical guidelines,28,32,34 two implemen-
ted a clinical protocol35,37 and one comprised a multi-
component intervention (education, decision support tool,
performance feedback).38 Three were based on a review of
current prescribing,25,33,36 and one incorporated a review of
prescribing and the introduction of a clinical protocol.31 Five
integrated computerized decision support or risk assessment
tools into their systems21–23,27,30 and four were based on
medical care programs offering HCP training and HCP–
patient consultations.24,26,29,39 To improve OACprescription,
six interventions used action and monitoring techni-
ques,21–24,26,30 six combined education and interventional
techniques with action and monitoring,25,27,32,33,37,39 four
attempted to use persuasion plus educational and interven-
tional techniques,28,35,36,40 one used persuasion plus action
and monitoring31 and three were multifaceted, using per-
suasive, educational and interventional and action andmon-
itoring techniques.29,34,38
Interventions were delivered by a range of professionals,
with eight delivered by either researchers or a combination
of researchers and HCPs such as primary, secondary and
tertiary care clinicians, nurses, pharmacists, allied HCPs and
software suppliers.21–23,25,27,28,33,37 Ten interventions were
delivered by HCPs only, including secondary care clinicians,
GPs, primary care teams, clinical pharmacists, allied and
nursing HCPs and local clinical stakeholders. Two interven-
tions had unspeciﬁed deliverers.24,32 Five interventions
were aimed at improving OAC prescribing among
GPs,21–23,28,38 three at hospital physicians,24,25,27 one at
cardiologists,26 four at interdisciplinary primary care
teams,29,31,37,39 one at an interdisciplinary hospital
team,40 two at hospital prescribers30,32 and four at hospital
clinicians and GPs.33–36
Follow-Up
Of the 12 uncontrolled studies, only Bajorek et al provided
follow-up beyond the post-intervention data (3- and 6-
month follow-up).33 Of the three RCTs, one provided a
maximum follow-up of 11 months22 and two provided
data at 12 months.21,23 Four of the ﬁve controlled trials
provided data from historical control groups that com-
menced 4 months,25 127,28 year and 3 years26 before the
intervention cohorts, respectively. The ﬁnal controlled study
reported an average follow-up length of 25 months24
(►Supplementary Table S2, available in the online version).
Fidelity
Measures assessing the ﬁdelity of the interventions to the
intended method were provided by four studies.22–24,40
Hsieh et al reported that the proportion of HCPs completing
ﬁve stroke quality measures increased from 75% before the
intervention to 86% during the intervention.40 Arts et al
monitored the triggers for notiﬁcations and the usage of their
notiﬁcation system, reporting 3,848 notiﬁcations, of which
188 (5%) were clicked on for further information, 76 were
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Table 3 Effectiveness of interventions by study characteristics
Characteristic Category Change in appropriate OAC prescription/
use (total n ¼ 20 studies)




2010 and after 10/13 3/13
Country EU 10/12 2/12
Non-EU 5/8 3/8
Study design Uncontrolled or historical control 13/16 3/16
Concurrent control 2/4 2/4
Setting Primary care 7/9 2/9
Secondary care 5/7 2/7
Tertiary care 3/4 1/4
Date of data
collection
Commenced pre-2010 10/12 2/12
Commenced 2010 and after 4/6 2/6
Unknown 1/2 1/2
Type of AF All/unspeciﬁed 10/15 5/15
Chronic 3/3 0/3
Non-valvular 2/2 0/2
Severity of AF CHADS2 or CHA2DS2-VASc 2 or 75 years old
or high-risk according to guidelines
5/8 3/8
CHADS2 and CHA2DS2-VASc 1 or 65 years old,
or moderate- and high-risk according to guidelines
6/7 1/7
Unknown/any severity 4/5 1/5
Intervention Computerized risk assessment tool 2/5 3/5
Education/guidelines/protocol 7/7 0/7
Medical care program 4/4 0/4
Review of prescribing 2/4 2/4
Intervention
focus
Action and monitoring 4/6 2/6
Educational and interventional; Action and monitoring 3/6 3/6
Educational and interventional; Persuasive 4/4 0/4
Persuasive; Action and monitoring 1/1 0/1
Educational and interventional;




Health care professional (HCP) 9/10 1/10





Primary care interdisciplinary team 4/4 0/4
Secondary care/Secondary and primary care/
Secondary care interdisciplinary team
8/11 3/11
Comparator Control health care settings (usual care) 3/5 2/5
Usual care at the same site prior to the
intervention or a historical control
12/15 3/15
Abbreviations: AF, atrial ﬁbrillation; EU, European Union; GP, general practitioner; OAC, oral anticoagulant.
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actively responded to, of which 44 (58%)were dismissed, and
32 (42%) were accepted, indicating the advice would be
followed.22 Boriani et al reported that the ANGELS of AF
reports were the speciﬁc trigger for prescribing OACs to 22
(10.5%) patients of the 209 not already receivingOACs.24Holt
et al obtained data from 12/23 intervention practices on
HCPs’ responses to screen prompts and their invitations to
patients to discuss OAC prescription23; 466 patients were
identiﬁed by the system as eligible at baseline, 159 (34%) of
these were conﬁrmed as eligible by HCPs and 35 (22%) of
these were prescribed OACs.23 Themean proportion of those
originally identiﬁed as eligible who converted to OACs
was 4.2%.23
Study Quality
The three cluster RCTs21–23were at low riskofmany sources of
bias; however, one RCT did not report control group data at
follow-up.21 One common potential source of performance
biaswasHCPs being aware of their groupallocation. Of theﬁve
non-randomized controlled studies,24–28 three used historical
controls25–27 introducing a risk of bias due to changes in
guidance and prescribing behaviours over time. In controlled
studies, sample size calculations were either absent26,28 or
their suitability unclear,24,25,27 raising the possibility of non-
signiﬁcant results due to insufﬁcient sample sizes (ranging
from 213 to 5,339 patients); blinding of outcome assessments
was also poorly described in three studies.24,26,28 The cross-
sectional study also lacked a sample size calculation.29 The
before-after studies30–40 were generally at low risk of bias
according to the adapted version of the NIH assessment tool
used16 however, in 7 of the 11 studies the populationmay not
have been representative of those who would be eligible for
the intervention30,33,34,36–38,40 due to differences between
the study population and the general population in charac-
teristics such as age, ethnicity, deprivation level or co-morbid-
ities (►Supplementary Figs. S2–S5, available in the online
version).
Effectiveness
Of the 20 studies, 13 reported a signiﬁcant increase in appro-
priate OAC prescription/use post-intervention21,24,26,28–32
34,36,38–40; two reported an increase, though signiﬁcance was
unclear,35,37 and ﬁve reported no signiﬁcant effect on appro-
priate OAC prescription/use22,23,25,27,33 (►Tables 1 and 2,
further details in ►Supplementary Table S2, available in the
online version).
A greater proportion of non-signiﬁcant results were
reported among more effectively controlled study designs,
such as cluster RCTs and studies with a concurrent com-
parator (2/4), than uncontrolled studies or those with
historical controls (3/16). Studies conducted with high
stroke-risk patients were less likely to report signiﬁcant
ﬁndings (5/8) than those with patients at moderate-to-high
(6/7) or unknown risk of stroke (4/5). Non-signiﬁcant
results were more frequently reported by studies with
interventions based on computerized decision support
Records after duplicates removed
n = 12,807

















Ineligible study design: 
11
Not original data: 6
Studies included in 
narrative synthesis
n = 20
Records identified through 
database searching
n = 18,365
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ﬂowchart.
Thrombosis and Haemostasis Vol. 119 No. 2/2019
Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation Pritchett et al. 303
tools (3/5) and reviews of prescribing (2/4); with all studies
based on the education of HCPs or guideline/protocol
implementation (7/7) and medical care programs offering
training to the HCP and HCP–patient consultations (4/4)
reporting signiﬁcant improvements in appropriate OAC
prescription. Those interventions based on action and
monitoring techniques or both action and monitoring and
education and intervention (of which 5/12 were computer-
ized decision support tools) were the least likely to report
signiﬁcant improvements in appropriate OAC prescription
(7/12). Interventions with a persuasive element were the
most likely to report signiﬁcant improvements in appro-
priate OAC prescription: 8/8 versus 7/12 studies with no
persuasive element.
Interventions partly delivered by researchers, were less
likely to report signiﬁcant improvements in OAC prescrip-
tion (4/8) than those delivered by HCPs (9/10); however, 5/8
of the researcher-delivered interventions were based on
computerized decision support models, the majority of
which reported non-signiﬁcant results (3/5). None of the
interventions delivered by researchers contained a persua-
sive element—a noteworthy characteristic of effective stu-
dies—with 8/8 interventions with a persuasive element
reporting signiﬁcant improvements in appropriate OAC
prescription (►Table 3).
Clinical Outcomes
Clinical outcomes such as the rates of stroke, transient
ischaemic attack (TIA), embolism and haemorrhage follow-
ing the intervention were only provided by two studies.24,41
Boriani et al reported no difference in the annual embolic
event rate in the intervention compared with control group
patients (p ¼ 0.64).24 Holt et al reported a signiﬁcantly
higher median (interquartile range) incidence of throm-
boembolic events per 1,000 patients at 6 months in the
intervention compared with the control group (10.3 [0,
16.3 vs. 0 [0, 7.75]]) (p ¼ 0.03); there was no difference at
12-month follow-up.23 Haemorrhagic events were non-sig-
niﬁcantly higher in the control group compared with the
intervention group at 6 and 12 months.23
Discussion
This reviewexamined the effectiveness and characteristics of
studies designed to increase appropriate OAC prescription in
eligible AF patients for stroke prevention. Despite published
reviews focusing on improving patient uptake of OACs,42,43
this review represents the ﬁrst rigorously conducted sys-
tematic evaluation of interventions to improve HCPs’ pre-
scribing behaviours in this ﬁeld. Research published to date
represents a wide variety of study designs, settings, inter-
ventions and theoretical approaches. This heterogeneity, the
substantial proportion of uncontrolled studies and the rela-
tively small number of studies overall, should be borne in
mind when considering our ﬁndings.
Overall, 15 of the 20 included studies reported improve-
ments in appropriate prescription of OACs in eligible AF
patients for stroke prevention, indicating that such inter-
ventions can be effective in inﬂuencing HCPs’ prescribing
behaviours. Trials with a concurrent comparator were less
likely to report signiﬁcant improvements, raising questions
about the appropriateness of uncontrolled study designs
during the last decade, and strongly indicating the need for
controlled studies to support appropriate conclusions. Stu-
dies with high stroke-risk AF patients (CHA2DS2-VASc 2 or
according to guidelines) were less likely to show improve-
ment in appropriate OAC prescription than those with
participants at moderate-high or unspeciﬁed stroke risk.
This ﬁnding may reﬂect the reported reluctance of HCPs to
prescribe OACs to patients over 65 years who are likely to be
at greater risk of stroke but also of falls and subsequent
haemorrhage.9
Certain intervention designs appeared to be less effective
in modifying HCPs’ prescribing behaviours than others, such
as computerized decision support tools and reviews of
current prescribing. The integration of computerized deci-
sion support tools within electronic medical record systems
is very common now; however, the greater the number of
reminders or alerts a HCP receives the less likely they are to
respond.44 This alert fatigue,44 may limit effectiveness of
such interventions. Reviews of prescribing were often con-
ducted by pharmacists, and it may be that clinicians respond
better to interventions conducted by peer clinicians as
discussed below.
Interventions based on HCP education, implementing
guidelines or protocols and medical care programs were
the most effective. The majority of HCP education and
guideline/protocol implementation interventions had an
element of persuasion in their theoretical focus (often
facilitating HCP involvement in local guideline production
or comparing HCPs’ practice with peers). In contrast, a
systematic overview of the theoretical foci of studies in
HCP behavioural change reviews indicated that interven-
tions with persuasive elements have proffered inconsistent
results. However, some success has been reported by stu-
dies using local opinion leaders to promote evidence-based
practice in HCPs.45 Most of the effective medical care
programs, and HCP education and guideline/protocol imple-
mentation interventions were conducted by clinicians or
multidisciplinary groups. It may be that interventions
enabling clinicians to seek consensus with, and receive
expert opinion from, their peer group are particularly
effective in prompting behavioural change. These ﬁndings
suggest that persuasive interventions based on HCP–peer
group interaction, or both HCPs and patients in medical care
programs, may be effective models for prompting beha-
vioural change in OAC prescription for stroke prevention in
eligible AF patients. These ﬁndings may also be useful for
intervention design in other ﬁelds where HCP behavioural
change is sought; however, large-scale cluster RCTs are
required to determine the most effective HCP behaviour
change interventions with greater certainty.
Strengths
This article represents the ﬁrst systematic review of inter-
ventions to improve appropriate OAC prescription in
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eligible AF patients for stroke prevention. Despite the
inclusion of only 20 studies, this research was based on
29,868 patients seen in 392 health care setting providing
primary, secondary and tertiary care. This review was
methodologically robust, with independent, duplicated
screening, data extraction and quality assessment pro-
cesses. Translation of non-English language papers guaran-
teed the inclusion of appropriate material. The main
outcome was change in rate of OAC prescription to eligible
AF patients for stroke prevention; rate of OAC use was only
considered if the intervention was aimed only at HCPs. This
distinction guaranteed that we explored the effect of the
interventions directly on the HCP, not the patient. Addi-
tionally, the theoretical underpinnings of studies were
examined to provide suggestions regarding the most
effective elements, as recommended by the Medical
Research Council. This approach is unique to a review in
this ﬁeld.
Limitations
Substantial heterogeneity in study design prohibited meta-
analysis of individual results, preventing authors from
drawing quantiﬁable conclusions regarding the effective-
ness of interventions overall. This heterogeneity limits the
certainty of conclusions drawn regarding the effectiveness
of different study characteristics. Only 4 of the 20 included
studies had concurrent controls, with the majority having
either historical control or no control data, introducing a
substantial risk of bias. This review included a compara-
tively small total number of studies (n ¼ 20); however, the
large total patient population (29,868 patients at baseline)
and the consistency of many of the ﬁndings adds conﬁdence
to our observations. The lack of measures reporting the
ﬁdelity of the interventions to the intended method in the
included studies creates uncertainty as to the effective
elements within interventions, which should be addressed
in the design of future studies. It should also be noted that
the included studies provided very little consideration of
the effect of their interventions on clinical outcomes, such
as rates of stroke, haemorrhage and TIA. Future studies
should include long-term follow-up of relevant clinical
outcomes to improve their clinical relevance for both
HCPs and patients.
Conclusion
AF is a growing global issue. Current research suggests that
in many countries HCPs are still under-prescribing OACs in
high stroke-risk patients and over-prescribing in low-risk
patients. Effective interventions are needed to improve
appropriate prescription of OACs in eligible AF patients to
prevent unnecessary risk of stroke and haemorrhage. This
review suggests that effective interventions should include
persuasive elements delivered by HCPs to HCPs or multi-
disciplinary teams. HCP education, implementing guide-
lines/protocols and medical care programs with education
for both HCPs and patients may all be effective interven-
tions. These ﬁndings may also inform development of
behavioural change interventions for HCPs in other health
care ﬁelds.
What is known about this topic?
• AF is an increasing international health concern.
AF affects over 33 million people worldwide with
prevalence increasing globally. The growth of the aging
population in developed countries is a substantial
contributing factor.
• Poor global guideline adherence in OAC prescription.
Despite recent improvements, greater guideline-
adherence is needed worldwide in the prescription
of OACs to eligible AF patients for stroke prevention.
Under-prescription in higher stroke-risk patients,
including those over 65 years, and substantial over-
prescription in those at low risk is still reported
globally, putting patients at unnecessary risk of stroke
and haemorrhage.
What does this paper add?
• The ﬁrst review of interventions aimed at HCPs.
This is the ﬁrst systematic review of interventions
speciﬁcally designed to improve HCPs’ appropriate
prescription of OACs in eligible AF patients for stroke
prevention.
• Effective interventions could improve guideline adher-
ence, reducing stroke and haemorrhage.
This review provides an indication of which inter-
vention designs and theoretical foci may be most
effective. Effective, practical, behaviour change inter-
ventions could be readily integrated into health care
systems and have the potential to increase appropri-
ate OAC prescription in eligible AF patients for stroke
prevention, reducing rates of avoidable stroke and
haemorrhage.
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